Abstract
Several cross-sectional studies have reported a relationship between elevated serum activity of liver enzymes [e.g. alanine aminotransferase (ALT) and gamma-glutamyltransferase (γGT)] and metabolic syndrome (MetS) and/or diabetes mellitus (DM). Raised serum activity of liver enzymes independently predicted the future development of MetS and DM as well as cardiovascular (CV) events and/or total/CV mortality in prospective studies. However, this association was not consistently demonstrated and it appears to be independent of alcohol intake. Even though these associations can be partly attributed to non-alcoholic fatty liver disease (NAFLD) and insulin resistance, there may be additional underlying mechanisms that contribute to the increased CV risk (e.g. inflammation and oxidative stress). The association of γGT with atherosclerotic plaque is of particular importance. The present review considers the link between serum liver enzyme activities and vascular risk. The links with DM and MetS are also discussed.
Keywords: Liver enzyme, alanine aminotransferase, gamma-glutamyltransferase, aspartate aminotransferase, non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, metabolic syndrome, diabetes mellitus, atherosclerotic plaque
Current Pharmaceutical Design
Title: Liver Enzymes: Potential Cardiovascular Risk Markers?
Volume: 17 Issue: 33
Author(s): Eirini Lioudaki, Emmanuel S. Ganotakis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Liver enzyme, alanine aminotransferase, gamma-glutamyltransferase, aspartate aminotransferase, non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, metabolic syndrome, diabetes mellitus, atherosclerotic plaque
Abstract: Several cross-sectional studies have reported a relationship between elevated serum activity of liver enzymes [e.g. alanine aminotransferase (ALT) and gamma-glutamyltransferase (γGT)] and metabolic syndrome (MetS) and/or diabetes mellitus (DM). Raised serum activity of liver enzymes independently predicted the future development of MetS and DM as well as cardiovascular (CV) events and/or total/CV mortality in prospective studies. However, this association was not consistently demonstrated and it appears to be independent of alcohol intake. Even though these associations can be partly attributed to non-alcoholic fatty liver disease (NAFLD) and insulin resistance, there may be additional underlying mechanisms that contribute to the increased CV risk (e.g. inflammation and oxidative stress). The association of γGT with atherosclerotic plaque is of particular importance. The present review considers the link between serum liver enzyme activities and vascular risk. The links with DM and MetS are also discussed.
Export Options
About this article
Cite this article as:
Lioudaki Eirini, S. Ganotakis Emmanuel and P. Mikhailidis Dimitri, Liver Enzymes: Potential Cardiovascular Risk Markers?, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220945
DOI https://dx.doi.org/10.2174/138161211798220945 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory, Gastrointestinal and Hepatoprotective Effects of Ocimum sanctum Linn: An Ancient Remedy with New Application
Inflammation & Allergy - Drug Targets (Discontinued) Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Oxytocin as a Potential Adjuvant Against COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial:
Current Diabetes Reviews Exogenous Hormonal Regulation in Breast Cancer Cells by Phytoestrogens and Endocrine Disruptors
Current Medicinal Chemistry The Usefulness of Phalangeal Quantitative Ultrasound in the Assessment of Skeletal Status in Children and Adolescents
Current Medical Imaging Resistin: A Promising Therapeutic Target for the Management of Type 2 Diabetes Mellitus?
Drug Design Reviews - Online (Discontinued) A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and Low-molecular Weight Heparin – Molecular Mechanisms
Current Pharmaceutical Biotechnology Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Editorial [Hot topic: New Developments in the Treatment and Prevention of Vascular Disease - Part 1 (Executive Editors: N. Katsiki, V.G. Athyros and D.P. Mikhailidis)]
Current Pharmaceutical Design Screening for Liver Disease - are LFTs Old HAT?
Current Medicinal Chemistry Glucose Transport Regulators
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm
Current Alzheimer Research Preventive Antidepressant use in Patients with Hepatitis C Treated with Interferon-Alfa: a Systematic Review
Current Psychiatry Reviews “Something is Wrong in the Ras Kingdom” - Evidence for the Involvement of p21Ras/MAP Kinase in Autoimmune Diseases
Current Rheumatology Reviews A Possible Link of Gut Microbiota Alteration in Type 2 Diabetes and Alzheimer’s Disease Pathogenicity: An Update
CNS & Neurological Disorders - Drug Targets An Association between MicroRNA-21 Expression and Vitamin D Deficiency in Coronary Artery Disease
MicroRNA p38 Mitogen-Activated Protein Kinase: A Critical Node Linking Insulin Resistance and Cardiovascular Diseases in Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuroprotective Effects of Exercise Treatments After Injury: The Dual Role of Neurotrophic Factors
Current Neuropharmacology